Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Rick Steves Prefers Paying A Bit Extra For This Delectable Food When Dining In Spain - 2Step by step instructions to Analyze Senior Insurance Contracts Really.
- 3She just became the first wheelchair user to travel to space
- 4Extraordinary Snowboarding Objections All over the Planet
- 5My prescription costs what?! Pharmacists offer tips that could reduce your out-of-pocket drug costs
- Experience Arranging: Planning for Epic Excursions
- These 2 companies are teaming up to offer insurance for space debris strikes on satellites
- This ‘CSI: Miami’ star spent years solving crimes on TV. Then she became the target of one herself.
- Two Indonesian UN peacekeepers killed in explosion in Lebanon
- The most effective method to Pick The Right Speakers
- 'The Beast in Me' arrives on Netflix: Is it based on a true story? And what drew Claire Danes to it? What to know about the thriller series.
- Ergonomic Office Seats for Work spaces
- Police arrest 18 as anti-war protests spread across Tel Aviv, Haifa, Jerusalem
- Damaged Shenzhou-20 spacecraft to return to Earth uncrewed for inspection
